Deal Tracker · Years

Emerging-market pharma deals in 2025

27 pharma deals announced in 2025 across GCC, MENA, Global (LMICs) & Southeast Asia, tracked by EPT — localization, licensing & distribution. Most active: Local Content and Government Procurement Authority, Bayer, Bio-Thera Solutions & Jamjoom Pharma. Latest: Biocon → Ajanta Pharma (Licensing, 23 Dec 2025).

27
deals tracked
30
countries involved
$930m
disclosed value (3 deals)
33%
localization, the top deal type
  • EPT has tracked 27 emerging-market pharma deals in 2025.
  • The most common structures are localization (33%), licensing (30%) & distribution (15%).
  • The countries that appear most often are Saudi Arabia (16), Egypt (4), UAE (4) & China (3).
  • Values were disclosed for 3 of 27 deals, totalling $930m; the largest is AriBio → Arcera Life Sciences ($600m, 10 Jun 2025).
  • The most active companies: Local Content and Government Procurement Authority (4), Bayer (2), Bio-Thera Solutions (2) & Jamjoom Pharma (2).

Countries involved

Saudi Arabia (16) · Egypt (4) · UAE (4) · China (3) · Germany (3) · India (2)

Largest disclosed deals

Questions

How many emerging-market pharma deals in 2025 has EPT tracked?
27 as of 23 Dec 2025. The most recent is Biocon → Ajanta Pharma (Licensing, 23 Dec 2025).
What types of emerging-market pharma deals in 2025 are most common?
Technology transfer / Localization: 9 (33%); Licensing: 8 (30%); Distribution: 4 (15%); Partnership / Collaboration: 4 (15%).
Which companies are most active in emerging-market pharma deals in 2025?
Local Content and Government Procurement Authority (4 deals), Bayer (2 deals), Bio-Thera Solutions (2 deals), Jamjoom Pharma (2 deals), Lifera (2 deals), Tabuk Pharmaceuticals (2 deals).
What is the largest disclosed emerging-market pharma deal in 2025?
AriBio → Arcera Life Sciences: $600m (Licensing, 10 Jun 2025); Faes Farma → SIFI: $310m (M&A / Acquisition, 2 Sept 2025); IMGSA → Omani Investment: $20m (Partnership / Collaboration, 3 Nov 2025). Values are as announced by the parties.
Which countries appear most in emerging-market pharma deals in 2025?
Saudi Arabia (16), Egypt (4), UAE (4), China (3), Germany (3), India (2) — counting where the parties are based and the markets the deals cover.

Browse deals

By region

GCC (83) · MENA (66) · Africa (17) · Latin America (17) · Southeast Asia (17) · Global (LMICs) (14) · CIS & Central Asia (13) · Türkiye (5) · Global ex-US (1)

By country

Saudi Arabia (69) · UAE (61) · China (31) · Egypt (27) · United States (26) · Oman (20) · India (19) · Switzerland (18) · Jordan (14) · South Korea (14) · Kazakhstan (13) · Algeria (12) · Türkiye (12) · United Kingdom (11) · Brazil (10) · Kuwait (10) · Iraq (8) · Morocco (8) · Bahrain (7) · Malaysia (7) · Spain (7) · Argentina (6) · Germany (6) · Indonesia (6) · Philippines (6) · Qatar (6) · Italy (5) · Mexico (5) · Vietnam (5) · France (4) · Taiwan (4) · Tunisia (4) · Canada (3) · Chile (3) · Denmark (3) · Greece (3) · Japan (3) · Lebanon (3) · Nigeria (3) · Pakistan (3) · South Africa (3) · Sweden (3) · Thailand (3) · Azerbaijan (2) · Colombia (2) · Ireland (2) · Kenya (2) · Libya (2) · Netherlands (2) · Singapore (2) · Uruguay (2) · Uzbekistan (2)

By year

2026 (193) · 2024 (6) · 2022 (3) · 2021 (2)

By therapeutic area

Multi-therapy (64) · Oncology (30) · Metabolic / Diabetes (27) · Cardiovascular (17) · Vaccines (15) · Immunology / Inflammation (13) · Rare / Orphan (9) · Infectious Disease (8) · CNS / Neurology (6) · Ophthalmology (6) · Consumer health (5) · Women's Health (4) · Respiratory (2)